Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Roel, Mulder"'
Autor:
N. Quenel Tueux, Norbert P Koper, T.J. Tan, Agostina Stradella, T. Crook, Santiago Escrivá-de-Romaní, E. van den Tweel, S. Ladoire, J.S. Lim, Philippe Aftimos, Roel Mulder, G. Bianchi, M. Oesterholt, Joyce O'Shaughnessy, A. Armstrong, N. Turner, C. Saura Manich
Publikováno v:
Annals of Oncology. 32:S1288
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e44eaee8b84e8acf3cc9b595843a1d15
https://doi.org/10.1016/j.annonc.2021.08.2088
https://doi.org/10.1016/j.annonc.2021.08.2088
Autor:
Karin Lubbers-Geuijen, Tinie van Boekel, Jochem Eigenhuijsen, Benny de Wit, Roel Mulder, Jos Verhagen, Karin de Laat-Arts, Marijn Buurman, David Egging
Publikováno v:
Bioanalysis. 10(16)
Aim: Detection and characterization of antidrug antibodies (ADA) play a key role in understanding the relation of ADA with safety and efficacy. Positive controls (PCs) are used to estimate the sensitivity and assay sensitivity in the presence of drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068a103fef6b3f41497f3a3800ad363d
https://pubmed.ncbi.nlm.nih.gov/30130133
https://pubmed.ncbi.nlm.nih.gov/30130133
Autor:
Evelyn van den Tweel, Jeffrey A. Cohen, Christian Wolf, Krzysztof Selmaj, Roel Mulder, Frederik Barkhof, David Egging, Janine Oberye, Anna N. Belova, Norbert P Koper
Publikováno v:
Multiple Sclerosis, 23(14), 1909-1917. SAGE Publications Ltd
Selmaj, K, Barkhof, F, Belova, A N, Wolf, C, van den Tweel, E R W, Oberyé, J J L, Mulder, R, Egging, D F, Koper, N P, Cohen, J A & on behalf of the GATE study group 2017, ' Switching from branded to generic glatiramer acetate : 15-month GATE trial extension results ', Multiple Sclerosis, vol. 23, no. 14, pp. 1909-1917 . https://doi.org/10.1177/1352458516688956
Multiple Sclerosis (Houndmills, Basingstoke, England)
Selmaj, K, Barkhof, F, Belova, A N, Wolf, C, van den Tweel, E R W, Oberyé, J J L, Mulder, R, Egging, D F, Koper, N P, Cohen, J A & on behalf of the GATE study group 2017, ' Switching from branded to generic glatiramer acetate : 15-month GATE trial extension results ', Multiple Sclerosis, vol. 23, no. 14, pp. 1909-1917 . https://doi.org/10.1177/1352458516688956
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Open-label 15-month follow-up of the double-blind, placebo-controlled Glatiramer Acetate clinical Trial to assess Equivalence with Copaxone® (GATE) trial. Objective: To evaluate efficacy, safety, and tolerability of prolonged generic gla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e9ed4de2c4d60a6e7d9e3d5dae9379
https://research.vumc.nl/en/publications/6d1e79f7-6544-4e88-998d-f081c2bec390
https://research.vumc.nl/en/publications/6d1e79f7-6544-4e88-998d-f081c2bec390
Autor:
Cristina Saura, Fiona C Thistlethwaite, Elisabeth G.E. de Vries, Simon Lord, Iain R. Macpherson, Philippe Aftimos, Sylvie Rottey, Udai Banerji, Valentina Boni, Marta Gil Martin, Jill J.J. Geenen, Roel Mulder, Christian Rolfo, Ferry A.L.M. Eskens, Carla M.L. van Herpen, Victor Moreno, E.C. Mommers, Norbert P Koper
Publikováno v:
Journal of Clinical Oncology. 36:1014-1014
1014Background: SYD985, (vic-)trastuzumab duocarmazine, is a HER2-targeting antibody-drug conjugate with a cleavable linker-duocarmycin payload that causes irreversible alkylation of the DNA in tum...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d34816246f08053e1b1e1224c3bf8748
https://doi.org/10.1200/jco.2018.36.15_suppl.1014
https://doi.org/10.1200/jco.2018.36.15_suppl.1014
Autor:
Peter, Kenemans, Nigel J, Bundred, Jean-Michel, Foidart, Ernst, Kubista, Bo, von Schoultz, Piero, Sismondi, Rena, Vassilopoulou-Sellin, Cheng Har, Yip, Jan, Egberts, Mirjam, Mol-Arts, Roel, Mulder, Steve, van Os, Matthias W, Beckmann, J, Pitkin
Publikováno v:
Lancet Oncology, 10(2), 135-146. Lancet Publishing Group
Kenemans, P, Bundred, N J, Foidart, J M, Kubista, E, von Schoultz, B, Sismondi, P, Vassilopoulou-Sellin, R, Yip, C H, Egberts, J C, Mol-Arts, M, Mulder, R, van Os, S & Beckmann, M W 2009, ' Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial ', Lancet Oncology, vol. 10, no. 2, pp. 135-146 . https://doi.org/10.1016/S1470-2045(08)70341-3
The lancet oncology
Kenemans, P, Bundred, N J, Foidart, J M, Kubista, E, von Schoultz, B, Sismondi, P, Vassilopoulou-Sellin, R, Yip, C H, Egberts, J C, Mol-Arts, M, Mulder, R, van Os, S & Beckmann, M W 2009, ' Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial ', Lancet Oncology, vol. 10, no. 2, pp. 135-146 . https://doi.org/10.1016/S1470-2045(08)70341-3
The lancet oncology
Summary Background Vasomotor symptoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer. Tibolone prevents both side-effects, but its effect on cancer recurrence is unknown. The aim of this study was to show n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c09ccce452b6ffc766334bdd6bd693b9
https://doi.org/10.1016/s1470-2045(08)70341-3
https://doi.org/10.1016/s1470-2045(08)70341-3
Autor:
Juan Planellas, Peter Kenemans, Rainer Kimmig, Giulia Moggio, Ernst Kubista, Roel Mulder, Piero Sismondi, Nicoletta Biglia, Jan Egberts, Mirjam Mol-Arts
Publikováno v:
Maturitas, 70(4), 365-372. Elsevier Ireland Ltd
Sismondi, P, Kimmig, R, Kubista, E, Biglia, N, Egberts, J, Mulder, R, Planellas, J, Moggio, G, Mol-Arts, M & Kenemans, P 2011, ' Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients-Data from LIBERATE trial ', Maturitas, vol. 70, no. 4, pp. 365-372 . https://doi.org/10.1016/j.maturitas.2011.09.003
Sismondi, P, Kimmig, R, Kubista, E, Biglia, N, Egberts, J, Mulder, R, Planellas, J, Moggio, G, Mol-Arts, M & Kenemans, P 2011, ' Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients-Data from LIBERATE trial ', Maturitas, vol. 70, no. 4, pp. 365-372 . https://doi.org/10.1016/j.maturitas.2011.09.003
Climacteric symptoms such as hot flushes and vaginal dryness are very common in breast cancer patients, resulting either from age or adjuvant therapy. Tibolone, a synthetic steroid, is effective in reducing these symptoms in healthy post-menopausal w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130bb1d5614e90a1c7afba54bcfd3c8a
https://www.ncbi.nlm.nih.gov/pubmed/22030384
https://www.ncbi.nlm.nih.gov/pubmed/22030384
Autor:
Roel Mulder
Publikováno v:
Bijzijn. 6:27-27
Iedere dag sterven er in Nederland ongeveer 378 mensen (cijfers CBS 2009). Een aantal hiervan overlijdt door een trauma, zelfdoding of drugsgebruik , maar de meesten mensen omdat zij ernstig ziek of op hoge leeftijd zijn. In een verpleeg- en verzorgi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18670a13b5a80790fa1e0056698258dc
https://doi.org/10.1007/s12415-011-0228-4
https://doi.org/10.1007/s12415-011-0228-4
Autor:
Roel Mulder
Publikováno v:
Bijzijn. 6:29-29
Complementaire zorg is extra zorg die zorgverleners geven naast de gebruikelijke standaardzorg. ten onrechte wordt het vaak gezien als alternatieve zorg, maar het verschil met alternatieve zorg is dat het bij complementair gaat om extra (aanvullende)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ff9d2407e92675cecc7cf48656dc2a7
https://doi.org/10.1007/s12415-011-0210-1
https://doi.org/10.1007/s12415-011-0210-1
Autor:
Roel Mulder
Publikováno v:
Bijzijn. 6:29-29
Bij wonden is het moeilijk om aan te geven hoe lang het duurt voordat deze weer helemaal geheeld zijn. Dit komt omdat er zoveel verschillende wonden zijn en er veel zaken zijn die van invloed zijn op het genezingsproces.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ec3afa34becb593a12492637d1639fd
https://doi.org/10.1007/s12415-011-0178-x
https://doi.org/10.1007/s12415-011-0178-x
Autor:
Roel Mulder
Publikováno v:
Bijzijn. 6:27-27
Bij relatief veel bewoners in een verpleeghuis komt COPD voor. Verzorgenden moeten wat activiteiten (ADL) betreft vaak een keuze maken tussen activiteiten overnemen en niet overnemen.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9388688cb182b7d73126e6fb9497d286
https://doi.org/10.1007/s12415-011-0031-2
https://doi.org/10.1007/s12415-011-0031-2